In “Radical”, Kate Pickert tells the story of how our approach to breast cancer has evolved over the decades, and the impact that our “culture” has had on that history.
This year we’ve seen some encouraging news with approvals of a targeted therapy and an immunotherapy for triple negative breast cancer.
There were some noteworthy developments this year in targeted therapies for hormone receptor-positive breast cancer.
New clinical trials will test whether the addition of progesterone could improve treatment for hormone receptor-positive breast cancer.
Cancer research stories worth following this fall include new developments in targeted treatment for ovarian cancer and for metastatic breast cancer.
The Breast Cancer Research Foundation provides seed grants for studies that have the potential for rapid clinical application in breast cancer.
When consumers have a better understanding of how clinical trials work they are most likely to say they would enroll in one, a recent study found.
How could sharing of data among researchers conducting clinical trials lead to better progress against cancer and more benefit for patients?
Is the end of cancer as a deadly disease now possible? Can we actually win the war on cancer, which has been pronounced a failure by many?
What progress is being made toward a blood test or “liquid biopsy” to aid in treatment or early detection of breast cancer?